These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27448155)

  • 1. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
    Kurt A; Andican G; Siva ZO; Andican A; Burcak G
    J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.
    Houjeghani S; Kheirouri S; Faraji E; Jafarabadi MA
    Nutr Res; 2018 Jan; 49():96-106. PubMed ID: 29420997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Taurine Supplementation on Metabolic Profiles, Pentosidine, Soluble Receptor of Advanced Glycation End Products and Methylglyoxal in Adults With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Esmaeili F; Maleki V; Kheirouri S; Alizadeh M
    Can J Diabetes; 2021 Feb; 45(1):39-46. PubMed ID: 32861603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentosidine plasma levels and relation with metabolic control in diabetic patients.
    Lapolla A; Reitano R; Baccarin L; Sartore G; Plebani M; Fedele D
    Horm Metab Res; 2005 Apr; 37(4):252-6. PubMed ID: 15952087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
    J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
    Yubero-Serrano EM; Woodward M; Poretsky L; Vlassara H; Striker GE;
    Clin J Am Soc Nephrol; 2015 May; 10(5):759-66. PubMed ID: 25710801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
    Hirata K; Kubo K
    Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
    O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
    J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P; Chattipakorn N
    J Bone Miner Metab; 2017 Nov; 35(6):631-641. PubMed ID: 27873077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
    Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
    Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prebiotic supplementation modulates advanced glycation end-products (AGEs), soluble receptor for AGEs (sRAGE), and cardiometabolic risk factors through improving metabolic endotoxemia: a randomized-controlled clinical trial.
    Farhangi MA; Dehghan P; Namazi N
    Eur J Nutr; 2020 Oct; 59(7):3009-3021. PubMed ID: 31728681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis.
    Drinda S; Franke S; Schmidt S; Stoy K; Lehmann T; Wolf G; Neumann T
    Complement Med Res; 2018; 25(3):167-172. PubMed ID: 29433120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE).
    Nowak A; Przywara-Chowaniec B; Damasiewicz-Bodzek A; Blachut D; Nowalany-Kozielska E; Tyrpień-Golder K
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
    Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
    Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
    Kanazawa I; Yamamoto M; Yamaguchi T; Sugimoto T
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):362-5. PubMed ID: 21472665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
    Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
    Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.